Zura Bio Reports 2025 Losses, Raises $144M to Extend Runway
Event summary
- Zura Bio reported a net loss of $68.7M for 2025, up from $52.4M in 2024, driven by increased R&D spending on Phase 2 programs.
- Raised $144M in February 2026 via public offering, extending cash runway to at least end of 2028.
- Phase 2 TibuSHIELD study enrollment expanded to 225 participants, with topline data expected Q4 2026.
- Appointed new CEO and two new board members in early 2026.
The big picture
Zura Bio's strategic focus on advancing its lead bispecific antibody, tibulizumab, comes amid intense competition in the autoimmune disease space. The company's ability to secure significant funding despite rising losses reflects investor confidence in its clinical pipeline, particularly as it prepares for key Phase 2 readouts. The appointments of new leadership and board members suggest a push for stronger governance as the company approaches critical value-creation milestones.
What we're watching
- Clinical Execution
- Whether Zura can deliver positive Phase 2 data for tibulizumab in HS and SSc, which would be critical for its valuation.
- Financial Discipline
- How effectively Zura manages its increased R&D spending while maintaining its extended cash runway.
- Competitive Positioning
- The pace at which Zura advances its pipeline relative to competitors in the autoimmune and inflammatory disease space.
Related topics